6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.

@article{Derijks20036ThioguanineSP,
  title={6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.},
  author={L J J Derijks and Dirk J de Jong and Lennard Petrus Lucia Gilissen and Leopold G. J. Engels and Piet M. Hooymans and Jan B. M. J. Jansen and Chris Jacob Johan Mulder},
  journal={European journal of gastroenterology & hepatology},
  year={2003},
  volume={15 1},
  pages={63-7}
}
OBJECTIVE 6-Mercaptopurine (6-MP) and azathioprine (AZA) have proven efficacy in the treatment of inflammatory bowel disease (IBD). However, adverse events leading to discontinuation may occur in 10-20% of patients. The efficacy of AZA and 6-MP is based on formation of their active metabolites, the 6-thioguaninenucleotides (6-TGNs). Therefore, 6-thioguanine (6-TG), an agent leading more directly to the formation of 6-TGNs and until recently used only in patients suffering from leukaemia, may be… CONTINUE READING